TRAILR4/TNFRSF10D/DcR2 Antibody [Unconjugated]

Recombinant Human TRAILR4/TNFRSF10D protein was serially diluted 2-fold and captured by Mouse Anti-Human TRAILR4/TNFRSF10D Monoclonal Antibody (MAB633R) coated on a Clear Polystyrene Microplate (DY990). Goat Anti-Human TRAILR4/TNFRSF10D Antigen Affinity-purified Polyclonal Antibody (Catalog # AF633) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (DY998) followed by Substrate Solution (DY999) and stopping the enzymatic reaction with Stop Solution (DY994).

In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (5 µg/mL, Catalog # MAB050) and the metabolic inhibitor actinomycin D (1 µg/mL), Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera (Catalog # 633-TR) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375‑TL) induced cytotoxicity in the L‑929 mouse fibroblast cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Under these conditions, inhibition of Recombinant Human TRAIL/TNFSF10 (12 ng/mL) activity elicited by Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera (10 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human TRAIL R4/TNFRSF10D Antigen Affinity-purified Polyclonal Antibody (Catalog # AF633). The ND50 is typically 0.03‑0.1 µg/mL.

• Reactivity: Hu
• Applications: WB, ELISA, Flow, IHC, B/N, CyTOF-ready
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

TRAILR4/TNFRSF10D/DcR2 Antibody [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human TRAIL R4/TNFRSF10D
  Ala56-His211
  Accession # Q9UBN6
• Specificity: Detects human TRAIL R4/TNFRSF10D in direct ELISAs and Western blots. In Western blots, less than 5% cross‑reactivity with recombinant human (rh) TRAIL R1, rhTRAIL R2, and rhTRAIL R3 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: TNFRSF10D
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • ELISA
  • Flow Cytometry 2.5 ug/10^6 cells
  • Immunohistochemistry 5-15 ug/mL
  • Neutralization 0.03-0.1 ug/mL
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TRAILR4/TNFRSF10D/DcR2 Antibody [Unconjugated]

• CD264 antigen
• CD264
• DcR2
• DCR2decoy with truncated death domain
• Decoy receptor 2
• TNF receptor-related receptor for TRAIL
• TNF-related apoptosis-inducing ligand receptor 4
• TNFRSF10D
• TRAIL R4
• TRAILR4
• TRAIL-R4
• TRAILR4TRAIL receptor 4
• TRUNDDTRAIL receptor with a truncated death domain
• tumor necrosis factor receptor superfamily member 10D
• tumor necrosis factor receptor superfamily, member 10d, decoy with truncateddeath domain

Background

Human TRAIL R4, also called decoy receptor 2 (DcR2) and TRUNND (TRAIL receptor with a truncated death domain), is a type 1, TNF R family membrane protein, which is a receptor for TRAIL (APO2 ligand). In the new TNF superfamily nomenclature, TRAIL R4 is referred to as TNFRSF10D. TRAIL R4 is unique among the TRAIL receptors in that its cytoplasmic domain contains a truncated consensus death domain motif. Binding of TRAIL R4 does not result in an apoptotic signal. Overexpression of TRAIL R4 can protect cells bearing TRAIL R1 and/or TRAIL R2 from TRAIL-mediated apoptosis. The human soluble TRAIL R4/Fc chimera neutralizes the ability of TRAIL to induce apoptosis.

1. Griffith, T.S. et al. (1998) Curr. Opin. Immunol. 10:559.
2. Pan, G. et al. (1998) FEBS lett 424:41.
3. Marsters, S.A. et al. (1997) Cur. Biol. 7:1003.
4. Degli-Esposti, M.A. et al. (1997) Immunity 7:813.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for TRAILR4/TNFRSF10D/DcR2 Antibody (AF633)(11)

Publications using AF633

• M Kopczynski, M Statkiewic, M Cybulska, U Kuklinska, K Unrug-Biel, Z Sandowska-, A Grochowska, M Gajewska, M Kulecka, J Ostrowski, M Mikula Cytotoxic Efficacy and Resistance Mechanism of a TRAIL and VEGFA-Peptide Fusion Protein in Colorectal Cancer Models International Journal of Molecular Sciences, 2021-03-19;22(6):. 2021-03-19 [PMID: 33808900] (ICC, Human)
• ?? ?rtykov, DA Belov, VO Shipunova, DB Trushina, SM Deyev, DA Dolgikh, MP Kirpichnik, ME Gasparian Chemotherapeutic Agents Sensitize Resistant Cancer Cells to the DR5-Specific Variant DR5-B more Efficiently than to TRAIL by Modulating the Surface Expression of Death and Decoy Receptors Cancers (Basel), 2020-04-30;12(5):. 2020-04-30 [PMID: 32365976] (Cell Culture, Human)
• Y Shlyakhtin, V Pavet, H Gronemeyer Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells Cell Death Dis, 2017-08-31;8(8):e3025. 2017-08-31 [PMID: 29048428] (Immunoprecipitation, Human)
• Sugimoto C, Merino KM, Hasegawa A, Wang X. Critical Role for Monocytes/Macrophages in Rapid Progression to AIDS in Pediatric Simian Immunodeficiency Virus-Infected Rhesus Macaques. J. Virol. 9/1/2017 [PMID: 28566378]
• M van Dijk, A Halpin-McCormick, T Sessler, A Samali, E Szegezdi Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways Cell Death & Disease 7/4/2013 [PMID: 23828565]
• Secchiero P, Melloni E, Corallini F, Beltrami AP, Alviano F, Milani D, D'Aurizio F, di Iasio MG, Cesselli D, Bagnara GP, Zauli G Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells. Stem Cells, 2008-09-04;26(11):2955-63. 2008-09-04 [PMID: 18772312] (Neutralization, Human)
• Zopf S, Neureiter D, Bouralexis S, Abt T, Glaser KB, Okamoto K, Ganslmayer M, Hahn EG, Herold C, Ocker M Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo. Int. J. Oncol., 2007-12-01;31(6):1391-402. 2007-12-01 [PMID: 17982666] (Western Blot, Human)
• Lane D, Cote M, Grondin R, Couture MC, Piche A Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3. Mol. Cancer Ther., 2006-03-01;5(3):509-21. 2006-03-01 [PMID: 16546965] (Western Blot, Human)
• Roux S, Lambert-Comeau P, Saint-Pierre C, Lepine M, Sawan B, Parent JL Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis. Biochem. Biophys. Res. Commun., 2005-07-22;333(1):42-50. 2005-07-22 [PMID: 15936719] (IHC-P, Human)
• Morel J, Audo R, Hahne M, Combe B Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J. Biol. Chem., 2005-01-31;280(16):15709-18. 2005-01-31 [PMID: 15684417] (Flow Cytometry, Human)
• Zauli G, Pandolfi A, Gonelli A, Di Pietro R, Guarnieri S, Ciabattoni G, Rana R, Vitale M, Secchiero P Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. Circ. Res., 2003-03-20;92(7):732-40. 2003-03-20 [PMID: 12649264] (Flow Cytometry, Human)

Bioinformatics

• Gene Symbol: TNFRSF10D
• Uniprot:
  • Q9UBN6()